|
【1】Letup MA.Baudouin C,Baum J,el al,The definition andclassification of dry eye disease:report of the definition andclassification subcommittee of the international dw eye WorkShopf2007).Ocul Surf.2007,5:75—92.
|
|
【2】Liana TU,Vesaluoma MH。Perez-Santonja JJ.et a1.Effect ofmyopic LASIK on corneal sensitivity and morphology 0f subbasalnei'ves.Invest Ophihalmol Vis Sci,2000,41:393-397.
|
|
【3】 McCabe E.Narayanan S.Advancements in anti—inflammatorytherapy for dry eye syndrome.Optometry.2009,80:555-566.
|
|
【4】Baudouin C.1.h。pathology 0f dry eye.Survey Ophthalmol,21101,45(Suppl2):s211一$220.
|
|
【5】Wilson SE,Ambrosio R.Laser in situ keratomileusis-inducedneurotM’phic epitheliopathy.Am J Ophthalmol+2001,132:405—406.
|
【6] |
Zoukhfi D.Effect of inflannnation on lacrimal gland function.Exp Eye Res.2006.82:885—898.
|
|
【7】Nichols Kk Patient-reported symptoms in dIy dye disease.OculSurf.20()6.4:137—145.
|
|
【8】Maitchouk DY,Beuernmn RW,Ohta T,et a1.Tear productionafter unilateral removal of the main lacrimal Sland in squirrelmonkeys.Arch Ophthalmel。2000.118:246—252.
|
|
【9】Zoukhfi D,Kublin CL.Impaired neurotransmiasion in lacrimaland salivary glands of a mufine model of Sjogren’s syndrome.Adv Exp Med Bi01.2002。506(Pt B):1023一1028.
|
|
【10】Wjlson SE,Mohan RR,Hung J,et a1.Apopt06is in the com∞in response to epithelial.injury:significance to wound healingand dry eye.Adv Exp Med Bid,2002.506(Pt B):821—826.
|
|
【ll】Brigntde F,Pisella PJ,Goldschild M,el a1.Flow eDomemeanalysis of inflammatory markers in conjunctival epithelial cellsof patients with dfy eyes.Invest Oplhthalmol Vis Sci,2000,41:1356-1363。
|
|
【12】Argueso P.Balaram M.Spurr-Michand S.et a1.Decreasedlevels of the gobtet eel/mucin MUC5AC in tears of patientswith Sjogren syndrome.Invest ophthalmol Vis Sei。2002。43:1004—1011.
|
|
【13】Zhao HC,Jumblatt JE,Wood TO,et al Quantification ofMUC5AC protein in hurm tears.Com∞.2001.加:873—877.
|
|
【14】De Paiva CS,Villarreal AL,Corrales RM,et a1.Dry eye—induced conjunctival epithelial squamous metaplasia is modulatedby interferon-gamma.Invest Ophthalmol Vis Sei。2007,48:2553—256cL
|
|
【15】Fabiani C,Barabino S.Rashid S,el a1.Corneal epithelialproliferation and thickness in n mouse model of dry eye.ExpEye Res.2009,89:166—171.
|
|
【161 u S,Nikulina K,DeVoss J。et a1.Small proliue-rieh protein1B(SPRRIB)is a biomarker for squamous metaplasia in dryeye disease.Invest Ophthalmol Vis Sci,2008,49:34--41.
|
|
【17】Chen YT.“S,Nikulina K,et at.Immune profile of sqnamousmetaplasia development in autoimmune ragulator-deficient dryeye.Mol Vis.2009.15:563—576.
|
|
【l 8】 Lj W,Hayashida Y,Chen YT,et a1.Air exposure inducedsquamous metaplasia of human limbal epithelium.InvestOphthalmol Vis Sci,2008,49:154一162.
|
|
【19】Peters K,Millar T.ne role of different phospholipids on tearbrcak-up time using a model eye.Curr Eye Res,2002,25:55d60.
|
|
【20】Management and therapy of dry eye disease:report 0f theManagement and Therapy Subcommittee of the InternationalDry Eye WorkShop(2007).Ocul Surf,2007,5:163—178.
|
|
【21】Aragona P,Stdo A,Ferreri F,el a1.Effects of the topicaltreatment with NSAIDs un coreeal sensitivity and ocular surfaceof Sjnga'en’s syndrome patients.Eye(Lond),2005,19:535—539.
|
|
【22】 Lekhanont K,Park CY,Smith JA,et a1.Effects of topicalanti•inflamnmiory agents in a botulinum toxin B•induced mollsemodel of kcratoconjunctivitis sicea.J Ocul Pharmacol Ther.2007,23:27—34.
|
|
【23】 Avunduk AM,Avunduk MC.Varaell ED,et a1.The comparisonof efficacies 0f topical eorticostemids and nonstemidal antiinflammatorydrops Oil dry eye patients:a clinical andimmunocytochemical study.Am J Uphthalmel。2003,136:593—602.
|
|
【24】Isawi H,Dhaliwal DK.Corneal melting and perforation inStevens Johnson syndrome following topical bromfenac use.JCataract Refraet Surg.2007,33:l悱1646.
|